Immunity to T cell receptor peptides in multiple sclerosis. III. Preferential immunogenicity of complementarity-determining region 2 peptides from disease-associated T cell receptor BV genes

Journal of Immunology

Volumn 161, Issue 2, 1998, Pages 1034-1044

  Bourdette, Dennis N ^a,b   Chou, Yuan K ^a,b   Whitham, Ruth H ^a,b   Buckner, Jane ^c,d   Kwon, Hi Jong ^e   Nepom, Gerald T ^c,d   Buenafe, Abigail ^a,b   Cooper, Shelley A ^b   Allegretta, Mark ^f   Hashim, George A ^g   Offner, Halina ^a,b   Vandenbark, Arthur A ^a,b  

^a PORTLAND VA MEDICAL CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c BENAROYA RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e St Paul's Hospital   (South Korea)

^f Bradley Pharmaceuticals Inc   (United States)

^g Council for Tobacco Research ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; T LYMPHOCYTE RECEPTOR;

ADULT; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; CLINICAL ARTICLE; CROSS REACTION; FEMALE; GENETIC COMPLEMENTATION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MOLECULAR RECOGNITION; MULTIPLE SCLEROSIS; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; RECEPTOR GENE; T LYMPHOCYTE ACTIVATION; VACCINATION;

ADULT; AMINO ACID SEQUENCE; CELL LINE; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; EPITOPES, T-LYMPHOCYTE; FEMALE; GENES, T-CELL RECEPTOR BETA; HLA-DR2 ANTIGEN; HUMANS; IMMUNE TOLERANCE; IMMUNODOMINANT EPITOPES; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MULTIPLE SCLEROSIS; PEPTIDE FRAGMENTS; PEPTIDE MAPPING; PROTEIN BINDING; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; T-LYMPHOCYTES; VACCINES, SYNTHETIC;

EID: 0032528428     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Vandenbark, A. A., G. Hashim, and H. Offner. 1993. TCR peptide therapy in autoimmune diseases. Int. Rev. Immunol. 9:251.
2. Burns, F. R., X. Li, N. Shen, H. Offner, Y. Chou, A. A. Vandenbark, and E. Heber-Katz. 1989. Both rat and mouse T cell receptors specific for the encephalitogenic determinant of myelin basic protein use similar Vα and Vβ chain genes even though the major histocompatibility complex and encephalitogenic determinants being recognized are different. J. Exp. Med. 169:27.
3. Vandenbark, A. A., G. Hashim, and H. Offner. 1989. Immunization with a synthetic T-cell receptor V-region peptide protects against experimental autoimmune encephalomyelitis. Nature 341:541.
4. Howell, M. D., S. T. Winters, T. Olee, H. C. Powell, D. J. Carlo, and S. W. Brostoff. 1989. Vaccination against experimental allergic encephalomyelitis with T cell receptor peptides. Science 246:668.
5. Offner, H., G. A. Hashim, and A. A. Vandenbark. 1991. T cell receptor peptide therapy triggers autoregulation of experimental encephalomyelitis. Science 251: 430.
6. Whitham, R. H., B. L. Kotzin, A. C. Buenafe, A. D. Weinberg, R. E. Jones, G. A. Hashim, C. M. Hoy, A. A. Vandenbark, and H. Offner. 1993. Treatment of relapsing experimental autoimmune encephalomyelitis with T cell receptor peptides. J. Neurosci. Res. 35:115.
7. + T cells in recovery from antigen-induced autoimmune disease. J. Exp. Med. 178:909.
8. Hashim, G. A., A. A. Vandenbark, A. B. Galang, T. Diamanduros, E. Carvalho, J. Srinivasan, R. Jones, M. Vainiene, W. J. Morrison, and H. Offner. 1990. Antibodies specific for a Vβ8 T cell receptor peptide suppress experimental autoimmune encephalomyelitis. J. Immunol. 144:4621.
9. Hafler, D. A., and H. L Weiner. 1989. MS: a CNS and systemic autoimmune disease. Immunol. Today 10:104.
10. Martin, R., H. F. McFarland, and D. E. McFarlin. 1992. Immunological aspects of demyelinating diseases. Annu. Rev. Immunol. 10:153.
11. Mokhtarian, F., D. E. McFarlin, and C. S. Raine. 1984. Adoptive transfer of myelin basic protein-sensitized T cells produces chronic relapsing demyelinating disease in mice. Nature 309:356.
12. Bourdette, D. B., A. A. Vandenbark, C. Meshul, R. Whitham, and H. Offner. 1988. Basic protein-specific T-cell lines that induce experimental autoimmune encephalomyelitis in SJL/J mice: comparison with Lewis rats. Cell. Immunol. 112:351.
13. Vandenbark, A. A., Y. K. Chou, J. Chilgren, D. Bourdette, R. Whitham, C. H.-J. Chou, G. Konat, M. Vainiene, and H. Offner. 1989. Human T lymphocyte response to myelin basic protein: selection of T lymphocyte lines from MBP-responsive donors. J. Neurosci. Res. 23:21.
14. Chou, Y. K., D. N. Bourdette, H. Offner, R. Whitham, R. Wang, G. A. Hashim, and A. A. Vandenbark. 1992. Frequency of T cells specific for myelin basic protein and myelin proteolipid protein in blood and cerebrospinal fluid in multiple sclerosis. J. Neuroimmunol. 38:105.
15. Zhang, J., S. Markovic-Plese, B. Lacet, J. Raus, H. L. Weiner, and D. A. Hafler. 1994. Increased frequency of Interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. J. Exp. Med. 179:973.
16. Allegretta, M., J. A. Nicklas, S. Sriram, and R. J. Albertini. 1990. T cells responsive to myelin basic protein in patients with multiple sclerosis. Science 247: 718.
17. Chou, Y. K., M. Vainiene, R. Whitham, D. Bourdette, C. H. J. Chou, G. Hashim, H. Offner, and A. A. Vandenbark. 1989. Response of human T lymphocyte lines to myelin basic protein: association of dominant epitopes with HLA class II restriction molecules. J. Neurosci. Res. 23:207.
18. Ebers, G. C. 1984. Immunogenetics and CSF studies in multiple sclerosis. In Immunoregulatory Processes in Experimental Allergic Encephalomyelitis and Multiple Sclerosis. A. A. Vandenbark and J. C. M. Raus, eds. Elsevier, Amsterdam, p. 233.
19. Oksenberg, J. R., M. A. Panzara, A. B. Begovich, D. Mitchell, H. A. Erlich, R. S. Murray, R. Shimonkevitz, M. Sherritt, J. Rothbard, C. C. A. Bernard, and L. Steinman. 1993. Selection of T-cell receptor Vβ-Dβ-Jβ gene rearrangements with specificity for a myelin basic protein peptide in brain lesions of multiple sclerosis. Nature 362:68.
20. Kotzin, B. L., S. Karuturi, Y. K. Chou, J. Lafferty, J. M. Forrester, M. Better, G. E. Nedwin, H. Offner, and A. A. Vandenbark. 1991. Preferential T cell receptor Vβ gene usage in myelin basic protein reactive T cell clones from patients with multiple sclerosis. Proc. Natl. Acad. Sci. USA 88:9161.
21. Offner, H., and A. A. Vandenbark. 1997. T cell receptor V genes in multiple sclerosis: increased use of Vα8 and Vβ5 in MBP-specific clones. Int. Rev. Immunol. In press.
22. Bourdette, D. N., R. H. Whitham, Y. K. Chou, W. J. Morrison, J. Atherton, C. Kenny, D. Liefeld, G. A. Hashim, H. Offner, and A. A. Vandenbark. 1994. Immunity to T cell receptor peptides in multiple sclerosis. I. Successful immunization of patients with synthetic Vβ5.2 and Vβ6.1 CDR2 peptides. J. Immunol. 152:2510.
23. Chou, Y. K., W. J Morrison, A. D. Weinberg, R. Dedrick, R. Whitham, D. N. Bourdette, G. Hashim, H. Offner, and A. A. Vandenbark. 1994. Immunity to T cell receptor peptides in multiple sclerosis. II. T cell recognition of Vβ5.2 and Vβ6.1 CDR2 peptides. J. Immunol. 152:2520.
24. Vandenbark, A. A., Y. K. Chou, R. Whitham, M. Mass, A. Buenafe, D. Liefeld, D. Kavanagh, S. Cooper, G. A. Hashim, H. Offner, and D. N. Bourdette. 1996. Treatment of multiple sclerosis with T-cell receptor peptides: results of a double-blind pilot trial. Nat. Med. 2:1109.
25. Vandenbark, A. A., Y. K. Chou, D. N. Bourdette, R. Whitham, and H. Offner. 1997. Immunogenicity is critical to the therapeutic application of T cell receptor peptide. Drug News Perspective 10(6):341.
26. Poser, C. M., D. W. Paty, L. Scheinber, W. I. MacDonald, F. A. Davis, G. C. Ebers, K. P. Johnson, W. A., Sibley, D. H. Silberberg, and W. W. Tourtellotte. 1983. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. 13:227.
27. Concannon, P., L. A. Pickering, P. Kung, and L. Hood. 1986. Diversity and structure of human T-cell receptor β-chain variable region genes. Proc. Natl. Acad. Sci. USA 83:6598.
28. Toyonaga, B., and T. W. Mak. 1987. Genes of the T cell antigen receptor in normal and malignant T cells. Annu. Rev. Immunol. 138:2213.
29. Choi, Y., B. Kotzin, L. Herron, J. Callahan, P. Marrack, and J. Kappler. 1989. Interaction of staphylococcus aureus toxin "superantigens" with human T cells. Proc. Natl. Acad. Sci. USA 86:8941.
30. Kabat, E. A., T. T. Wu, H. M. Perry, K. S. Gottesman, and C. Foeller. 1991. In Sequences of Proteins of Immunologic Interest, 5th Ed. U.S. Department of Health and Human Services, Public Health Service, NIH Publication No. 91-3242, Washington, DC.
31. Hashim, G. A., E. D. Day, L. Fredane, P. Intintola, and E. Carvalho. 1986. Biological activity of region 65 to 102 of the myelin basic protein. J. Neurosci. Res. 16:467.
32. Taswell, C. 1981. Limiting dilution assays for the determination of immunocompetent cell frequencies. I. Data analysis. J. Immunol. 126:1614.
33. Kwok, W. W., G. T. Nepom, and F. C. Raymond. 1995. HLA-DQ polymorphisms are highly selective for peptide binding interactions. J. Immunol. 155: 2468.
34. Chou, Y. K., A. D. Weinberg, A. Buenafe, D. N. Bourdette, R. Whitham, J. A. R. Kaleeba, I. F. Robey, D. G. Kavanagh, H. Offner, and A. A. Vandenbark. 1996. MHC-restriction, cytokine profile, and immunoregulatory effects of human T cells specific for TCR Vβ CDR2 peptides: comparison with myelin basic protein-specific T cells. J. Neurosci. Res. 45:838.
35. Eylar, E. H., S. W. Brostoff, G. A. Hashim, J. Caccam, and P. Bernett. 1971. Basic A1 protein of the myelin membrane: the complete amino acid sequence. J. Biol. Chem. 246:5770.
36. Chomczynski, P., and N. Sacchi. 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162: 156.
37. Kimura N., B. Toyonaga, Y. Yoshikai, R. P. Du, and T. W. Mak. 1987. Sequences and repertoire of the human T cell receptor alpha and beta chain variable region genes in thymocytes. Eur. J. Immunol. 17:375.
38. Robinson, M. A. 1991. The human T cell receptor b-chain gene complex contains at least 57 variable gene segments: identification of six Vβ genes in four new gene families. J. Immunol. 146:4392.
39. Vandenbark, A. A., G. A. Hashim, and H. Offner. 1996. T cell receptor peptides in treatment of autoimmune disease: rationale and potential. J. Neurosci. Res. 43:391.
40. + T cells. Immunity 2:177.
41. Zhang, J., R. Medaer, P. Stinissen, D. Hafler, and J. Raus. 1993. MHC-restricted depletion of human myelin basic protein-reactive T cells by T cell vaccination. Science 261:1451.
42. Falcioni, F., D. Vidovic, E. S. Ward, D. Bolin, G. Singh, H. Shah, B. Ober, and Z. A. Nagy. 1995. Self tolerance to T cell receptor Vβ sequences. J. Exp. Med. 182:249.
43. Vainiene, M., G. G. Burrows, K. Ariail, I. Robey, A. A. Vandenbark, and H. Offner. 1996. Neonatal injection of Lewis rats with recombinant Vβ8.2 induces T cell but not B cell tolerance and increased severity of experimental autoimmune encephalomyelitis. J. Neurosci. Res. 45:475.
44. Ashton-Rickardt, P. G., A. Bandeira, J. R. Delaney, L. Van Kaer, H.-P. Pircher, R. M. Zinkernagel, and S. Tonegawa. 1994. Evidence for a differential avidity model of T cell selection in the thymus. Cell 76:651.
45. Vogt, A. B., H. Kropshofer, H. Kalbacher, M. Kalbus, H.-G. Rammensee, J. E. Coligan, and R. Martin. 1994. Ligand motifs of HLA-DRB5*0101 and DRB1*1501 molecules delineated from self-peptides. J. Immunol. 153:1665.
46. O'Sullivan, D., T. Arrhenius, J. Sidney, M.-F. del Guercio, M. Albertson, M. Wall, C. Oseroff, S. Southwood, S. M. Colon, F. C. A. Gaeta, and A. Sette. 1991. On the interaction of promiscuous antigenic peptides with different DR alleles: identification of common structural motifs. J. Immunol. 147:2663.
47. Margalit, H., J. L. Spouge, J. L. Cornette, K. B. Ease, C. DeLisi, and J. A. Bersofsky. 1987. Prediction of immunodominant helper T cell antigenic sites from the primary sequence. J. Immunol. 138:2213.
48. Wilson, D. B., A. B. Golding, R. A. Smith, T. Dafashy, J. Nelson, L. Smith, D. J. Carlo, S. W. Brostoff, D. P. Gold. 1997. Results of a phase I clinical trial of a T-cell receptor peptide vaccine in patients with multiple sclerosis. I. Analysis of T-cell receptor utilization in CSF cell populations. J. Neuroimmunol. 76:15.
49. Gold, D. P., R. A. Smith, A. B. Golding, E. E. Morgan, T. Dafashy, J. Nelson, L. Smith, J. Diveley, J. A. Laxer, S. P. Richieri, D. J. Carlo, S. W. Brostoff, and D. B. Wilson. 1997. Results of a phase I clinical trial of a T-cell receptor vaccine in patients with multiple sclerosis. II. Comparative analysis of TCR utilization in CSF T-cell populations before and after vaccination with a TCRVβ6 CDR2 peptide. J. Neuroimmunol. 76:29.